Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques

Inclusion Criteria: Sequence 1 (pathological specimens and information collection of pancreatic cancer patients): 1. Chinese patients, regardless of age and gender; 2. patients with pancreatic cancer confirmed by pathology; 3. Patients without a second primary tumor; 4. The clinical diagnostic information to be collected within three months before sampling is relatively complete. Sequence 2 (samples and information collection of patients with pancreatic cancer): 1. Chinese patients, regardless of age and gender; 2. Subjects must obtain informed consent and sign informed consent, indicating that they understand the purpose and procedure of this study and are willing to participate in the study; 3. Patients with pancreatic malignancy diagnosed by pathology; 4. Patients without a second primary tumor. Sequence 3 (healthy subject samples and information collection) 1. Chinese healthy male or female, aged 18-45; 2. Subjects must obtain informed consent and sign informed consent, indicating that they understand the purpose and procedure of this study and are willing to participate in the study; 3. Physical examination, vital signs, laboratory examination (blood routine, blood biochemistry and urine routine), 12 lead ECG and other normal or abnormal persons without clinical significance Exclusion Criteria: Sequence 1 : 1. The quality of pathological specimens of patients can not meet the requirements of proteomics; 2. The researchers believe that patients who are not suitable for proteomic analysis. Sequence 2: 1. patients with other malignant tumors (non pancreatic cancer metastasis). 2. hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive or syphilis antibody positive; 3. Pregnant or lactating women; 4. The researcher believes that it is not suitable to participate in this experiment. Sequence 3: 1. Abnormalities of clinical significance judged by clinicians, including physical examination, vital signs examination, ECG or clinical laboratory examination results; 2. hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive or syphilis antibody positive; 3. Those who have participated in other clinical trials of drugs and accepted clinical trials of drugs or devices for trial within the first three months; 4. Those vaccinated with active or attenuated vaccine within 1 month before screening or during the planned trial; 5. Pregnant or lactating women; 6. Those who have taken any drugs within the first 14 days; 7. The researcher believes that it is not suitable to participate in this experiment.